ストックスクリーナーアプリを入手
1.83
2.66%
-0.05
アフターアワーズ：
1.83
前日終値:
$1.88
開ける：
$1.9
24時間の取引高:
4,060
Relative Volume:
0.38
時価総額：
$21.70M
収益：
-
当期純損益:
$-3.15M
株価収益率:
-5.9961
EPS:
-0.3052
ネットキャッシュフロー:
$-2.23M
1週間 パフォーマンス:
-1.92%
1か月 パフォーマンス:
-15.67%
6か月 パフォーマンス:
-30.68%
1年 パフォーマンス:
+4.57%
1日の値動き範囲:
$1.83
$1.92
1週間の範囲:
$1.77
$1.95
52週間の値動き範囲:
$1.20
$4.0499
Cytomed Therapeutics Ltd Stock (GDTC) Company Profile
GDTC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GDTC
Cytomed Therapeutics Ltd
|
1.83 | 21.70M | 0 | -3.15M | -2.23M | -0.3052 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomed Therapeutics Ltd (GDTC) 最新ニュース
Published on: 2025-07-29 02:23:22 - metal.it
Does CytoMed Therapeutics Limited stock perform well during market downturnsCapitalize on trading strategies that deliver - jammulinksnews.com
What is the risk reward ratio of investing in CytoMed Therapeutics Limited stockUnrivaled growth potential - jammulinksnews.com
Price momentum metrics for CytoMed Therapeutics Limited explainedTechnical Trade Plan with Entry Checklist - Newser
What are analysts’ price targets for CytoMed Therapeutics Limited in the next 12 monthsCapitalize on fast-moving stock opportunities - jammulinksnews.com
CytoMed Therapeutics Limited Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
What drives CytoMed Therapeutics Limited stock priceExplosive market performance - jammulinksnews.com
Is CytoMed Therapeutics Limited a good long term investmentRapid-fire capital growth - jammulinksnews.com
How high can CytoMed Therapeutics Limited stock price go in 2025Daily Swing Candidates - Newser
What drives SDST stock priceConsistently profitable trades - Autocar Professional
The ANGELICA Trial and the Future of Allogeneic CAR-T: A Strategic Investment Perspective - AInvest
CytoMed's Breakthrough Cancer Cell Therapy Shows Promise in Phase 1 Trial, Advances to Higher Dose Testing - Stock Titan
GDTC advances CTM-N2D: Dose Level 1 complete, Phase I escalates | GDTC SEC FilingForm 6-K - Stock Titan
COST Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
Blue Chip Stocks High Precision Stock TipsBreakthrough stock performance - jammulinksnews.com
What analysts say about CytoMed Therapeutics Limited stockExceptional profit velocity - jammulinksnews.com
How CytoMed Therapeutics Limited stock performs during market volatilitySmart Money Trade Setups - Newser
What makes CytoMed Therapeutics Limited stock price move sharplySafe and Scalable Investment Tips - Newser
Why CytoMed Therapeutics Limited stock attracts strong analyst attentionTrade With Low Risk Exposure - Newser
CytoMed Therapeutics shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
CytoMed Therapeutics shareholders approve all proposals at annual meeting - Investing.com
The Pipeline for of iPSC-Derived Cell Therapeutics in 2025 - BioInformant
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shel - GuruFocus
CytoMed Therapeutics Files $50 Million Mixed Shelf - MarketScreener
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shelf Offering | GDTC Stock News - GuruFocus
CytoMed Therapeutics schedules annual shareholder meeting - Investing.com Australia
CytoMed Therapeutics schedules annual shareholder meeting By Investing.com - Investing.com India
CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.4% – Here’s Why - Defense World
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
CytoMed Therapeutics Reports Full Year Ended December 31, - GlobeNewswire
CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan
Cytomed Therapeutics Ltd shares rise 3.08% intraday after Osteopore secures EU approval for custom orthopaedic and cranial implants. - AInvest
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight - The Globe and Mail
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com
SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy - Express Healthcare
SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative Gamma Delta T-cell cancer therapy in India - Pharmabiz.com
CytoMed Partners with SunAct for Groundbreaking Cancer Cell Therapy Trial in India - Stock Titan
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - simplywall.st
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
CytoMed Therapeutics Acquires Cord Blood Banking License and 12,000 CBUs; Will Develop Cord Blood-derived Biologics through It Subsidiary, LongevityBank - BioInformant
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Yahoo Finance
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - GlobeNewswire
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
iPSC Applications in Cell Therapy, Drug Discovery, and Beyond - BioInformant
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Cytomed Therapeutics Ltd (GDTC) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
0.15%
大文字化:
|
ボリューム (24 時間):